Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment
Addresses $50+ billion combination cancer therapy market projected to grow 8.5% annually through 2030
Over 60% of cancer patients received DNA damaging agents or DNA repair inhibitors as part of their clinical treatment and unique AI-powered module will focus on predicting the efficacy, safety and biomarker signatures associated with those potential treatments
Platform successfully guided FDA-cleared Phase 1B/2 trial design for LP-184 + olaparib in triple-negative breast cancer
DALLAS, July 15, 2025--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a pioneering artificial intelligence (AI) company transforming oncology drug discovery and development, today announced the launch of an innovative AI-powered module within its proprietary RADR® platform, designed to predict the activity and efficacy of combination regimens involving DNA-damaging agents (DDAs) and DNA damage response inhibitors (DDRis) in clinical cancer treatment. With the global market for combination cancer therapies projected to exceed $50 billion by 2030, growing at a CAGR of 8.5%, this module represents a significant advancement in precision oncology, enabling faster, more cost-effective development of tailored therapeutic regimens. Leveraging this AI-driven framework, Lantern Pharma has successfully architected and achieved FDA clearance for a Phase 1B/2 clinical trial in triple-negative breast cancer (TNBC), focusing on a novel DDA-DDRi combination regimen with promising preclinical efficacy.
In a peer-reviewed study published in Frontiers in Oncology, Clinical outcomes of DNA-damaging agents and DNA damage response inhibitors combinations in cancer: a data-driven review, Lantern Pharma researchers systematically analyzed 221 DDA-DDRi combination-arm clinical trials, involving 22 DDAs and 46 DDRis, to develop this module. The study categorized DDAs into eight subclasses (e.g., alkylating agents, interstrand cross-linkers) and DDRis into 14 subclasses (e.g., PARP, ATR, WEE1 inhibitors). From these, 89 trials with interpretable outcomes were scored for clinical effectiveness, safety, and biomarker-driven responses, providing a robust dataset to train the AI module.1
Transforming Cancer Combination Therapy Development
The new AI module represents a paradigm shift in precision oncology, leveraging machine learning to predict which drug combinations will be most effective for specific patient populations while minimizing toxicity risks. This data-driven approach has already demonstrated its value by successfully guiding the design of Lantern's FDA-cleared Phase 1B/2 clinical trial combining LP-184 with olaparib in triple-negative breast cancer (TNBC).
"This AI-powered module is a transformative step in our mission to deliver personalized cancer treatments," said Panna Sharma, CEO & President of Lantern Pharma. "By leveraging our RADR® platform to analyze complex multi-omics and clinical trial data, we identified optimal DDA-DDRi combinations that guided the development of our TNBC trial. We believe this approach could reduce combination therapy development timelines and costs by one-third compared to traditional methods."
The module integrates genomic, transcriptomic, and clinical data to predict synergistic drug interactions, optimize therapeutic outcomes, and identify biomarker-defined patient subpopulations likely to respond to specific combinations. This data-driven approach directly informed the design of Lantern's FDA-cleared Phase 1B/2 trial in TNBC for LP-184 and olaparib, with potential to improve response rates and reduce toxicity.
Key insights from the study powering the AI module include:
Non-PARP Inhibitor Promise: Non-PARP DDRi combinations, particularly WEE1 inhibitors like adavosertib with platinum agents, showed an 80% positive outcome rate in interstrand cross-linker trials, with strong efficacy in TP53-mutated cancers, directly informing future trial design.
Biomarker-Driven Success: Biomarkers such as TP53 mutations and HRD signatures were critical predictors of response, enabling patient stratification to maximize efficacy.
Toxicity Mitigation: The use of novel formulations like liposomal doxorubicin in combination regimens reduced cardiotoxicity, providing a safer backbone for combination strategies.
Emerging Trends: The analysis emphasizes the patterns in treatment effectiveness, safety, and emerging trends across various cancer types and discusses the potential of biomarkers to guide treatment selection and improve patient outcomes.
The module's multi-agentic framework integrates specialized AI agents for data aggregation, drug classification, predictive modeling, biomarker identification, and optimization, creating a dynamic system that is planned to evolve along with new data. The system's continuous learning capability ensures adaptability, enabling Lantern to refine regimens and accelerate future trials across diverse cancer indications. The company is exploring licensing and commercialization opportunities to expand the application of this technology, further revolutionizing combination therapy development.
About Lantern Pharma
Lantern Pharma (NASDAQ: LTRN) is an AI-driven biotechnology company focused on accelerating and optimizing the discovery, development, and commercialization of cancer therapies. Its RADR® platform leverages artificial intelligence and machine learning to uncover novel therapeutic opportunities, accelerate drug development, and improve patient outcomes.
Please find more information at:
Website: www.lanternpharma.com
LinkedIn: https://www.linkedin.com/company/lanternpharma/
X: @lanternpharma
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "model," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that we may not be able to secure sufficient future funding when needed and as required to advance and support our existing and planned clinical trials and operations, (ii) the risk that observations in preclinical studies and early or preliminary observations in clinical studies do not ensure that later observations, studies and development will be consistent or successful, (iii) the risk that our research and the research of our collaborators may not be successful, (iv) the risk that we may not be successful in licensing potential candidates or in completing potential partnerships and collaborations, (v) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (vi) the risk that no drug product based on our proprietary RADR® AI platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (vii) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on March 27, 2025. You may access our Annual Report on Form 10-K for the year ended December 31, 2024 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.
1 Fontenot R, Biyani N, Bhatia K, Ewesuedo R, Chamberlain M and Sharma P (2025) Clinical outcomes of DNA-damaging agents and DNA damage response inhibitors combinations in cancer: a data-driven review. Front. Oncol. 15:1577468. doi: 10.3389/fonc.2025.1577468
View source version on businesswire.com: https://www.businesswire.com/news/home/20250715020079/en/
Contacts
Investor Contact Investor Relationsir@lanternpharma.com +1-972-277-1136
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a few seconds ago
- Yahoo
Business confidence subdued amid tariffs but 'worst-case' less likely: BoC survey
A pair of reports from the Bank of Canada say tariff-related uncertainty continued to put a damper on business and consumer sentiment in the second quarter, but the worst-case trade scenarios previously anticipated seem less likely. The central bank's business outlook survey said 28 per cent of firms are now planning for a recession in Canada, down from 32 per cent last quarter but still up from 15 per cent over the previous two quarters. Sales outlooks remain pessimistic overall due to widespread concerns about the effects of a slowing economy, but the report says recent monthly surveys suggest some improvement in firms' outlooks, especially among exporters because few have been directly affected by current tariffs. Meanwhile, the Canadian survey of consumer expectations says spending intentions have weakened further because of persistent tariff threats. Consumers also continue to see the labour market as soft amid "elevated" fears of job loss. The reports come ahead of the Bank of Canada's next interest rate decision and monetary policy report set for July 30. This report by The Canadian Press was first published July 21, 2025. Sammy Hudes, The Canadian Press Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a few seconds ago
- Yahoo
This Energy Infrastructure Company Boasts Stable Cash Flows and High Payouts
Enbridge Inc. (NYSE:ENB) is included among the 12 Best Oil and Gas Dividend Stocks to Buy Now. A large natural gas pipeline snaking through a rural landscape. As one of the only dividend aristocrats in its sector, Enbridge Inc. (NYSE:ENB) has increased its dividend for 30 consecutive years and expects to continue this momentum by growing its business by 5% per year through the end of the decade. Currently, the company offers a quarterly dividend of C$0.9425 per share and has a dividend yield of 5.96%, as of July 15. Enbridge Inc. (NYSE:ENB) boasts a toll-booth-like pipeline and utility business that centers around fixed fees and other contracts that generate stable cash flows, allowing the company to maintain its dividend growth at a CAGR of 9% over the past three decades. The company is also diversifying beyond pipelines and into renewable energy through solar and wind projects. Moreover, it reported a secured growth backlog of $28 billion at the end of Q1 2025, ensuring sustainable cash flow and dividend growth in the future. Enbridge Inc. (NYSE:ENB) is a midstream energy company that focuses on transporting and distributing oil, natural gas, and natural gas liquids. The Canadian company moves about 30% of the crude oil produced in North America. While we acknowledge the potential of ENB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Nuclear Energy Stocks to Buy Right Now and The 5 Energy Stocks Billionaires are Quietly Piling Into. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a few seconds ago
- Yahoo
7 credit score myths you should stop believing
If you've ever learned anything about credit scores from a friend, a family member, or social media, I'm sorry to tell you this, but you may have some unlearning to do. In my past role as an NFCC-certified credit counselor and my cumulative 12 years working as a financial educator, I've heard some bizarre myths and rumors about credit scores, a few of which are really popular. Sure, myths can be fun. But when it comes to credit scores, they have major consequences. Some of the most commonly held myths can leave you with perpetually low credit scores and make it hard for you to qualify for mortgages or credit cards. Here are the most common and harmful credit myths I've come across, and the truth you need to know about each one. This embedded content is not available in your region. Top credit score myths debunked 1. Checking your credit reports lowers your scores When I encourage people to pull their credit reports, I tend to hear the same response: "Won't that hurt my credit scores?" The answer is a firm "no!" The truth is, pulling your own credit reports does not hurt your credit scores at all. In fact, if you don't pull and review your reports, you may never be able to build good credit. That's because reviewing your reports helps you with all of the following: Finding out what's in your credit file Discovering what needs to be improved Finding and disputing credit report errors Catching signs of identity theft You can pull your credit reports for free once a week at 2. You need to carry a balance to build good credit I wish I had a dollar for every time someone told me that carrying a 30% credit card balance (that's a balance equal to 30% of your card limit) helps you build good credit scores. The reality is that the lower your credit card balance is, the better for both your credit scores and your wallet. When you have low balances, you reduce your credit utilization ratio (the amount of credit you're using compared to your total available balance). The lower your credit utilization, the better it is for your credit scores because you're showing lenders that you don't need credit cards to cover your expenses. Additionally, if you pay off your full credit card balance by the monthly due date — which I highly recommend — you can avoid high interest charges. 3. I don't need to worry about my credit until I want a loan In my credit counseling days, I often got calls from people who wanted help fixing their credit ASAP. Often, it was because they had just submitted an application for a car loan, or made an offer on a new home. Unfortunately, I had to let them know that it usually takes months, and sometimes years, to clean up credit mistakes and build good credit. For example, even if you pay off your credit card today, it can take a month or more for the $0 balance to show up on your credit reports and be factored into your credit scores. And if you want to build good credit scores, it can take months or even years, depending on the condition your credit is in now. 4. Paying off collection debt helps your credit scores I receive several emails a month from people who are desperate to remove old collection accounts from their credit reports. The reason? They want to improve their credit scores — fast. Unfortunately, there's no guarantee that paying off a collection account will improve your credit scores. Here are a few credit score facts to keep in mind before you consider sending money to a debt collector: Medical collection debt under $500 has no impact on your credit scores. Paying off a collection account does not remove the account from your credit reports. Most credit score calculations do not make a distinction between paid and unpaid collections. That said, depending on the type of debt, you may want to pay off collection accounts anyway. It can stop debt collectors from contacting you or even taking legal action against you. However, if the debt is old and close to falling off your report (typically seven years from the original delinquency), paying may reset the clock on the debt. So, if you're unsure about how to handle a debt in collections, it's a good idea to reach out to an accredited credit counselor for guidance. 5. Disputing accurate information will improve your credit scores Most credit myths are a mix of truth and fiction, and this one is no different. Here's what's true: If you find an error in your credit reports, you have the right to file a dispute (for free) and get the information corrected or removed. But you do not have the right to get accurate information removed from your reports. Unfortunately, some people view the dispute process as an invitation to try and remove any negative information, even if it's accurate. In fact, there are credit repair companies that charge money to dispute correct information on your behalf. If you do dispute correct information, there's a chance it will be removed from your reports while the credit bureau investigates your claim. But once they confirm that it's accurate, the information will reappear on your reports. 6. A good credit score means you're rich Wealth doesn't impact your credit scores, at least not directly. Yes, your income level can impact how much money you borrow, whether you're able to repay loans and credit cards, and other behaviors that affect your credit. However, your income is not a factor in determining your credit scores. In fact, even if you're considered rich, but you don't pay your debt on time, you will have poor credit scores. 7. Bad credit history follows you forever As a credit counselor, I spoke to many people who believed that a bankruptcy or foreclosure from the '80s or '90s was still damaging their credit. While events such as bankruptcy, foreclosure, and repossession will cause severe damage to your credit scores, the damage only follows you for a limited time. Here's a breakdown of the timelines: 7 years: Missed debt payments (at least 30 days late), vehicle repossession, home foreclosure, and Chapter 13 bankruptcy. 10 years: Chapter 7 bankruptcy and positive credit information As negative information gets older, it has less of an impact on your credit scores. Once it's removed, it has no impact at all. Up Next Up Next
